Drug Profile


Alternative Names: ONO-7058; ONX-012; ONX-0912; OPZ; PR-047

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onyx Pharmaceuticals
  • Class Amides; Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules; Thiazoles
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I/II Haematological malignancies; Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
  • 01 Jan 2017 Amgen initiates enrolment in the INTREPID-1 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT02939183)
  • 03 Dec 2016 Final adverse events and efficacy data from a phase Ib/II trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top